N@N

BioDelivery Sciences to Present at Rodman & Renshaw, Baird, and Stifel Nicolaus Investor Conferences

_{//health-fitness.news-articles.net/content/2010/ .. rd-and-stifel-nicolaus-investor-conferences.html}
^{Published in Health and Fitness on Wednesday, September 8th 2010 at 6:51 GMT by Market Wire}  

RALEIGH, N.C.--([ BUSINESS WIRE ])--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation at three upcoming investor conferences. Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at each conference where he will focus on BDSIa™s product pipeline, including BEMA Buprenorphine for pain and opioid dependence, and BEMA Granisetron for the prevention of chemotherapy induced nausea and vomiting.

• Rodman & Renshaw Annual Global Investment Conference
  Monday, September 13 at 3:40 p.m. Eastern Time
  New York Palace Hotel, New York City.

• Baird 2010 Healthcare Conference
  Wednesday, September 15 at 9:00 a.m. Eastern Time
  St. Regis New York, New York City.

• Stifel Nicolaus 2010 Healthcare Conference
  Thursday, September 16 at 10:55 a.m. Eastern Time
  Four Seasons Hotel, Boston.

Each presentation will be webcast live and can be accessed at [ www.bdsi.com ]. For those who are not available to listen to the live broadcast, the presentations will be archived.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSIa™s pain franchise currently consists of two products utilizing the Companya™s patented BEMA buccal soluble film technology. ONSOLIS (fentanyl buccal soluble film) was approved by FDA on July 16, 2009 for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licensed to Meda AB, who launched ONSOLIS in the U.S., and Kunwha Pharmaceutical Co. Ltd. BDSIa™s second pain product, BEMA Buprenorphine, completed Phase2 clinical development for the treatment of pain; a higher dose formulation is being developed for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA aTriptana). BDSIa™s headquarters is located in Raleigh, North Carolina. For more information visit [ www.bdsi.com ].

BDSI^® and BEMA^® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS^® is a registered trademark of Meda Pharmaceuticals, Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the aCompanya) related thereto or at the presentation described herein contain, or may contain, among other things, certain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Companya™s plans, objectives, projections, expectations and intentions and other statements identified by words such as aprojects,a amay,a acould,a awould,a ashould,a abelieves,a aexpects,a aanticipates,a aestimates,a aintends,a aplans,a or similar expressions. These statements are based upon the current beliefs and expectations of the Companya™s management and are subject to significant risks and uncertainties, including those detailed in the Companya™s filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Companya™s control). The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.